AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31272313 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes based on clinical/HIV-related reasons
Number of subjects: 368
Study 27943511 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Quit
Number of subjects: 409
Study 27943511 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation material (control)
Number of subjects: 409
Study 26473333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TwHF (2.0 mg·kg·d)
Number of subjects: 198
Study 26473333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TwHF (1.5 mg·kg·d)
Number of subjects: 198
Study 26473333 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine (3 g/d)
Number of subjects: 198
Study 23003915 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX-β-TCP + EDTA
Number of subjects: 30
Study 23003915 — intervention group
Group type: COMPARATOR
Intervention: DOX-β-TCP
Number of subjects: 30
Study 21586714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (7000 μg of retinol equivalents as retinyl palmitate)
Number of subjects: 125257
Study 21586714 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene supplementation (42 mg of all-trans beta carotene)
Number of subjects: 125257
Study 21586714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125257
Study 21586714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 125257
Study 21586714 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene supplementation
Number of subjects: 125257
Study 19095033 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa
Number of subjects: 100
Study 19095033 — intervention group
Group type: COMPARATOR
Intervention: Td+pa
Number of subjects: 100
Study 16723217 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5mg
Number of subjects: 551
Study 16723217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 14688378 — intervention group
Group type: EXPERIMENTAL
Intervention: CML66-L peptide
Number of subjects: 0
Study 14688378 — intervention group
Group type: EXPERIMENTAL
Intervention: CML66-L
Number of subjects: 0
Study 11903320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH) trials
Number of subjects: 0
Study 11903320 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control and sodium restriction
Number of subjects: 0
Study 11903320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish and weight control
Number of subjects: 0
Study 11903320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein and fibre
Number of subjects: 0
Study 11903320 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee drinking
Number of subjects: 0
Study 11903320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary anti-oxidants
Number of subjects: 0
Study 9356116 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (M) 36 microg/kg
Number of subjects: 24
Study 9356116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (F) 2.4 microg/kg
Number of subjects: 24
Study 9356116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (B) 0.6 microg/kg F, 9 microg/kg M
Number of subjects: 24
Study 8160279 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (5 ml/kg/d for three days)
Number of subjects: 44
Study 8160279 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment with antibiotics and fresh plasma/whole blood transfusions)
Number of subjects: 44
Study 3947216 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam disodium
Number of subjects: 163
Study 3947216 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate and tobramycin sulfate
Number of subjects: 163
Study 3947216 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon injuries
Number of subjects: 163
Study 29488676 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin alone or in combination with oral hypoglycaemic drugs; prescribed to 24.4% to 34.5% of patients with diabetes.
Number of subjects: 24012
Study 29488676 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin prescription in the administrative registry.
Number of subjects: 24012
Study 27600290 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 448
Study 27600290 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 448
Study 27600290 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 448
Study 24708643 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-standardised acupuncture plus rescue medication (cetirizine)
Number of subjects: 422
Study 24708643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture plus rescue medication (cetirizine)
Number of subjects: 422
Study 24708643 — intervention group
Group type: COMPARATOR
Intervention: Rescue medication (cetirizine) alone
Number of subjects: 422
Study 24708643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 422
Study 23046781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 23046781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) with written accounts (WA) component
Number of subjects: 0
Study 20367631 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF applications
Number of subjects: 26
Study 20367631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17608342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynesys dynamic stabilization system
Number of subjects: 101
Study 16275187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 64
Study 12366861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip + Scaling and Root Planing (Sc/Rp)
Number of subjects: 13
Study 12366861 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (Sc/Rp)
Number of subjects: 13
Study 10428194 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling trial participation
Number of subjects: 588
Study 10428194 — intervention group
Group type: EXPERIMENTAL
Intervention: Media contacts
Number of subjects: 588
Study 10428194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer worry
Number of subjects: 588
Study 7503597 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT)
Number of subjects: 0
Study 7503597 — intervention group
Group type: COMPARATOR
Intervention: Current methods for colorectal cancer screening
Number of subjects: 0
Study 2097305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 348
Study 2097305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 7460803 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 49
Study 7460803 — intervention group
Group type: COMPARATOR
Intervention: Hyperviscous (no intervention)
Number of subjects: 49
Study 7460803 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 49
Study 30419799 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger maternal age
Number of subjects: 1653
Study 29855803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) 3 times per week for 8 weeks at 60-75% VO2peak
Number of subjects: 24
Study 29855803 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) refrained from any exercise training
Number of subjects: 24
Study 26910107 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 11
Study 24509894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (80 IU a day)
Number of subjects: 14
Study 24509894 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 14
Study 22216936 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 573
Study 22216936 — intervention group
Group type: COMPARATOR
Intervention: Control group (Project Toward No Drug Abuse)
Number of subjects: 573
Study 19462850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine pericardium
Number of subjects: 52
Study 19462850 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine pericardium
Number of subjects: 52
Study 19462850 — intervention group
Group type: COMPARATOR
Intervention: Autologous temporalis fascia
Number of subjects: 52
Study 17448056 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 N cricoid pressure
Number of subjects: 120
Study 17448056 — intervention group
Group type: COMPARATOR
Intervention: Sham cricoid pressure
Number of subjects: 120
Study 15345791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (estrogen)
Number of subjects: 0
Study 15345791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinstitution of estrogen or initiation/increase in antidepressant dose
Number of subjects: 0
Study 15345791 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of hormone therapy
Number of subjects: 0
Study 15345791 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (estrogen) or selective estrogen receptor modulator
Number of subjects: 0
Study 12393356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg
Number of subjects: 45
Study 12393356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg + epinephrine 200 microg
Number of subjects: 45
Study 12393356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg + clonidine 30 microg
Number of subjects: 45
Study 10439645 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 5 mg·kg‐1
Number of subjects: 40
Study 10439645 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg·kg‐1
Number of subjects: 40
Study 10439645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 10439645 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study 7598439 — intervention group
Group type: COMPARATOR
Intervention: WHO/UNICEF oral rehydration solution (ORS)
Number of subjects: 108
Study 7598439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented maize solution
Number of subjects: 108
Study 7598439 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfermented maize solution
Number of subjects: 108
Study 1694158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% and adrenaline 1:80000 without HES
Number of subjects: 20
Study 1694158 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% and adrenaline 1:80000 with 10% HES 200/0.5
Number of subjects: 20
Study 25847 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimepranol (TMP)
Number of subjects: 25
Study 25847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30365231 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality group (4-minute virtual reality video)
Number of subjects: 86
Study 30365231 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional education regarding perioperative process)
Number of subjects: 86
Study 30365231 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Number of subjects: 86
Study 30365231 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 28824012 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g of CLA daily for 3 months
Number of subjects: 74
Study 28824012 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil as placebo daily for 3 months
Number of subjects: 74
Study 25755251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion (Group A)
Number of subjects: 128
Study 25755251 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group A)
Number of subjects: 128
Study 25755251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion (Group B)
Number of subjects: 128
Study 25755251 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group B)
Number of subjects: 128
Study 23496092 — intervention group
Group type: EXPERIMENTAL
Intervention: I : E ratio of 1 : 1
Number of subjects: 100
Study 23496092 — intervention group
Group type: EXPERIMENTAL
Intervention: I : E ratio of 2 : 1
Number of subjects: 100
Study 23496092 — intervention group
Group type: EXPERIMENTAL
Intervention: I : E ratio of 1 : 2 PEEP
Number of subjects: 100
Study 23496092 — intervention group
Group type: COMPARATOR
Intervention: Conventional I : E ratio (Group 1 : 2)
Number of subjects: 100
Study 20963405 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9 eluted from BioMatrix II stents
Number of subjects: 27
Study 19058760 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 179
Study 19058760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 179
Study 19058760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 19058760 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Labetalol and Lisinopril combined)
Number of subjects: 179
Study 17204269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 16
Study 17204269 — intervention group
Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 16
Study 17204269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet enriched in alpha‐linolenic acid
Number of subjects: 16
Study 15028365 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 533
Study 15028365 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 533
Study 14763721 — intervention group
Group type: EXPERIMENTAL
Intervention: Day service attendance for six months
Number of subjects: 26
Study 14763721 — intervention group
Group type: COMPARATOR
Intervention: No attendance for six months
Number of subjects: 26
Study 10999088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in TBM patients
Number of subjects: 60
Study 10999088 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in non-TBM patients (viral encephalitis and enteric encephalopathy)
Number of subjects: 60
Study 10999088 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in pyogenic meningitis
Number of subjects: 60
Study 10999088 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid-adenosine deaminase (CSF-ADA) activity in cerebral malaria
Number of subjects: 60
Study 10999088 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of TBM using CSF-ADA levels
Number of subjects: 60
Study 7741285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiobarbiturate (5 mg/kg thiopental or thiamylal)
Number of subjects: 155
Study 7741285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybarbiturate (1.75 mg/kg methohexital)
Number of subjects: 155
Study 7741285 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 155
Study 7741285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiobarbiturate (5 mg/kg)
Number of subjects: 155
Study 2201652 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (LAC) 2 g/day
Number of subjects: 55
Study 2201652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6259941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing polymyxin, neomycin and bacitracin (PNB)
Number of subjects: 827
Study 6259941 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor ointment (PI2)
Number of subjects: 827
Study 6259941 — intervention group
Group type: COMPARATOR
Intervention: No topical agent (Control)
Number of subjects: 827
Study 6259941 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 827
Study 6259941 — intervention group
Group type: EXPERIMENTAL
Intervention: PI2
Number of subjects: 827
Study 6259941 — intervention group
Group type: EXPERIMENTAL
Intervention: PNB
Number of subjects: 827
Study 31593697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 0
Study 31593697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31825772 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-NOSF dressing
Number of subjects: 0
Study 31825772 — intervention group
Group type: COMPARATOR
Intervention: Neutral dressing (control)
Number of subjects: 0
Study 27845030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided capsule-preserved hydrodilatation with corticosteroid (1mL of 40mg/mL triamcinolone acetonide, 6mL of 1% lidocaine, and normative saline)
Number of subjects: 64
Study 27845030 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided IACI alone (1mL of 40mg/mL triamcinolone acetonide and 3mL of 1% lidocaine)
Number of subjects: 64
Study 26353875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 2% mupirocin plus topical antisepsis with chlorhexidine gluconate for 5 days
Number of subjects: 400
Study 26353875 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment and placebo cloths for skin antisepsis for 5 days
Number of subjects: 400
Study 24165586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotransplantation of CB and ex vivo expanded UCMSCs
Number of subjects: 20
Study 24165586 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 20
Study 21890077 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs) in patients with normal GFR (≥60 ml/min/1.73 m²)
Number of subjects: 4157
Study 21890077 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs) in patients with low GFR (<60 ml/min/1.73 m²)
Number of subjects: 4157
Study 21890077 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents in patients with low GFR (<60 ml/min/1.73 m²)
Number of subjects: 4157
Study 21890077 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents in patients with normal GFR (≥60 ml/min/1.73 m²)
Number of subjects: 4157
Study 19295193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 193
Study 19295193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 193
Study 17449421 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DZM)
Number of subjects: 50
Study 17449421 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 50
Study 15328386 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 (2.5 ng/kg/min)
Number of subjects: 9
Study 15328386 — intervention group
Group type: EXPERIMENTAL
Intervention: VML 588 (0.05, 0.20 and 0.40 mg/kg/h)
Number of subjects: 9
Study 11418315 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y Zevalin (0.4 mCi/kg therapeutic dose after 5 mCi tracer dose)
Number of subjects: 90
Study 11418315 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2 weekly x 4)
Number of subjects: 90
Study 11418315 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y Zevalin
Number of subjects: 90
Study 9593559 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complete reperfusion (TIMI grade 3)
Number of subjects: 2431
Study 9593559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction >40%
Number of subjects: 2431
Study 7925872 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to dust and solvents
Number of subjects: 0
Study 7925872 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of exposure to dust
Number of subjects: 0
Study 7925872 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-related estimates of exposure to dust based on work history
Number of subjects: 0
Study 7925872 — intervention group
Group type: EXPERIMENTAL
Intervention: Full work history to determine exposure to dust
Number of subjects: 0
Study 7925872 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to wood dust
Number of subjects: 0
Study 7925872 — intervention group
Group type: EXPERIMENTAL
Intervention: High probability of exposure to dust
Number of subjects: 0
Study 7925872 — intervention group
Group type: COMPARATOR
Intervention: None of the exposures
Number of subjects: 0
Study 29728552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 10
Study 29728552 — intervention group
Group type: COMPARATOR
Intervention: No laser therapy (Control)
Number of subjects: 10
Study 27741335 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 0
Study 27741335 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab every-other-week
Number of subjects: 0
Study 27741335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24740207 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7041 SNP (T allele)
Number of subjects: 1380
Study 24740207 — intervention group
Group type: EXPERIMENTAL
Intervention: rs705117 SNP (G allele)
Number of subjects: 1380
Study 24740207 — intervention group
Group type: EXPERIMENTAL
Intervention: rs12144344 SNP
Number of subjects: 1380
Study 23414650 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 1610
Study 23414650 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 1610
Study 21388079 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 210
Study 21388079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 75 mg
Number of subjects: 210
Study 21388079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 19477772 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending alcohol intoxication (from .08%) with instruction to maximize arousal
Number of subjects: 78
Study 19477772 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending alcohol intoxication (from .08%) with instruction to suppress arousal
Number of subjects: 78
Study 19477772 — intervention group
Group type: COMPARATOR
Intervention: Sober men with instruction to maximize arousal
Number of subjects: 78
Study 16431031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking women postpartum (protected, high risk, premature, ambivalent groups)
Number of subjects: 317
Study 14612643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 64
Study 14612643 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 64